Front. Neurol. Frontiers in Neurology Front. Neurol. 1664-2295 Frontiers Media S.A. 10.3389/fneur.2023.1209749 Neurology Review Pathology of myelin oligodendrocyte glycoprotein antibody-associated disease: a comparison with multiple sclerosis and aquaporin 4 antibody-positive neuromyelitis optica spectrum disorders TakaiYoshiki1* MisuTatsuro1 FujiharaKazuo12 AokiMasashi1 1Department of Neurology, Tohoku University Graduate School of Medicine, Sendai, Japan 2Department of Multiple Sclerosis Therapeutics, Fukushima Medical University, Fukushima, Japan

Edited by: Lekha Pandit, Nitte University, India

Reviewed by: Tanuja Chitnis, Harvard Medical School, United States; Elias S. Sotirchos, Johns Hopkins University, United States

 *Correspondence: Yoshiki Takai, y-takai@med.tohoku.ac.jp 21 07 2023 2023 14 1209749 21 04 2023 20 06 2023 Copyright © 2023 Takai, Misu, Fujihara and Aoki. 2023 Takai, Misu, Fujihara and Aoki

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Myelin oligodendrocyte glycoprotein (MOG) is expressed on the outermost layer of the myelin sheath in the central nervous system. Recently, the clinical concept of MOG antibody-associated disease (MOGAD) was established based on the results of human MOG-transfected cell-based assays which can detect conformation-sensitive antibodies against MOG. In this review, we summarized the pathological findings of MOGAD and discussed the issues that remain unresolved. MOGAD pathology is principally inflammatory demyelination without astrocyte destruction, characterized by perivenous demyelination previously reported in acute disseminated encephalomyelitis and by its fusion pattern localized in both the white and gray matter, but not by radially expanding confluent demyelination typically seen in multiple sclerosis (MS). Some of demyelinating lesions in MOGAD show severe loss of MOG staining compared with those of other myelin proteins, suggesting a MOG-targeted pathology in the disease. Perivascular cuffings mainly consist of macrophages and T cells with CD4-dominancy, which is also different from CD8+ T-cell-dominant inflammation in MS. Compared to aquaporin 4 (AQP4) antibody-positive neuromyelitis optica spectrum disorders (NMOSD), perivenous complement deposition is less common, but can be seen on myelinated fibers and on myelin degradation products within macrophages, resembling MS Pattern II pathology. Thus, the pathogenetic contribution of complements in MOGAD is still debatable. Together, these pathological features in MOGAD are clearly different from those of MS and AQP4 antibody-positive NMOSD, suggesting that MOGAD is an independent autoimmune demyelinating disease entity. Further research is needed to clarify the exact pathomechanisms of demyelination and how the pathophysiology relates to the clinical phenotype and symptoms leading to disability in MOGAD patients.

 myelin oligodendrocyte glycoprotein antibody acute disseminated encephalomyelitis perivenous demyelination confluent demyelination multiple sclerosis lesion pattern-II section-at-acceptance Multiple Sclerosis and Neuroimmunology Introduction

Myelin oligodendrocyte glycoprotein (MOG) is a glycoprotein (consisting of 218 amino acids) expressed in oligodendrocytes and is characterized by its distribution in the outermost layer of the myelin sheath (1). MOG is composed of multiple splicing variants (2, 3), all of which have extracellular immunoglobulin variable domains and thus belong to the immunoglobulin superfamily (4). Because of these structural features, MOG has a long history of research as an autoantigen that can induce inflammatory demyelinating pathology in the central nervous system (CNS) (5–9), and is one of the best-studied antigens in experimental autoimmune encephalomyelitis (EAE) (10–12). Therefore, autoantibodies against MOG have long been considered a potential cause of human inflammatory demyelinating diseases, particularly multiple sclerosis (MS). However, the discovery of clinically relevant MOG antibodies in human disease has not been successful until recently. Previous results on the detection of MOG antibodies by enzyme-linked immunosorbent assay (ELISA) or Western blot were confusing due to the low specificity (13). This is because the antigen is linear in ELISA or denatured in Western blot such that the three-dimensional structure of native MOG was lost; the issue was resolved when the conformation-sensitive MOG antibody became detectable by human MOG-transfected cell-based assays (CBAs) (14–16). As a result, MOG antibodies have been found in patients with optic neuritis, acute myelitis, neuromyelitis optica spectrum disorders (NMOSD) without aquaporin 4 (AQP4) antibodies (17, 18), acute disseminated encephalomyelitis (ADEM) (19, 20), and brainstem (21–23) and cerebral cortical encephalitis (24–26). In contrast, typical MS patients are essentially negative for MOG antibodies (27, 28). Consequently, patients with MOG antibodies came to be recognized as belonging to a group with inflammatory demyelinating conditions distinct from MS, and the international diagnostic criteria of MOG antibody-associated disease (MOGAD) were recently published (29).

In this review, we summarized the histopathological findings of MOGAD in published studies. In particular, we outlined the pathologies typically found in MOGAD and the issues that remain unresolved because of inconsistent results in previous studies. We also discussed the unique pathogenesis of MOGAD by comparing it with MS and AQP4 antibody-positive NMOSD (AQP4 + NMOSD).

 Histopathological features of MOGAD Patterns of demyelination

The pattern of demyelination seen in well-known inflammatory demyelinating diseases can be classified into “confluent demyelination” in MS, “perivenous demyelination” in ADEM and “concentric demyelination” in Balo’s disease (Figure 1) (30, 31). “Confluent demyelination” is characterized by fusion and enlargement of perivascular demyelinating lesions with well-defined borders, resulting in the formation of large plaques, and the lesions may occasionally exhibit a map-like morphology (Figure 1A). On the other hand, “perivenous demyelination” is the one with indistinct borders around a single small vessel with inflammatory cell infiltration, and often multifocal (Figure 1B). Perivenous demyelination is considered useful in the pathological differentiation of ADEM from MS (32). However, it should be noted that we may miss “perivenous demyelination” because it can be very small, and the activity of myelin phagocytosis by macrophages is sometimes scarce, requiring careful observation (Figure 2).

Various types of demyelination. (A) Confluent demyelination (SPMS). (B) Perivenous demyelination (ADEM). (C) Concentric demyelination (Balo’s disease). (D) Mixed pathology of confluent and perivenous demyelination (MOGAD). (A–D) Klüver-Barrera staining. ADEM, acute disseminated encephalomyelitis; MOGAD, myelin oligodendrocyte glycoprotein antibody-associated disease; SPMS, secondary progressive multiple sclerosis.

Perivenous demyelination in MOGAD. A demyelinating lesion was seen around small vessels with inflammatory cell infiltration. There were a small number of macrophages that phagocytosed myelin debris (insert in B). (A) MBP, (B) MOG (blue)/CD68 (brown). MBP, myelin basic protein; MOG, myelin oligodendrocyte glycoprotein; MOGAD, MOG antibody-associated disease.

The pathology of MOGAD is characterized by a mixture of perivenous and confluent demyelinating lesions (Figure 1D) (33, 34), and their proportions may depend on the timing of tissue sampling and disease severity (Tables 1, 2) (24, 33–47). The median time to tissue sampling in our study (one month) (33) was shorter than that in Höftberger et al. (seven months) (34) (Table 1), and the demyelination patterns in the two studies were different (90% of the lesions in our cases had perivenous demyelination, while 50% of the lesions in Höftberger’s study had a transitional pattern [a combination of perivenous and confluent demyelinations]). However, it is important to mention that among confluent demyelinating lesions, slowly expanding lesions (SELs) typically seen in the subacute to chronic stage of MS (Figure 3) (48) are rarely observed in MOGAD patients (34) or AQP4 + NMOSD patients (49). SELs are characterized by the accumulation of activated macrophages/microglia at the lesion edge with iron deposition (50), which is thought to be involved in the progression of MS (51–53). In other words, demyelinating lesion formation in MOGAD patients is characterized by simultaneous development of multiple perivascular inflammatory demyelination and its fusion to form confluent demyelination, which is different from radial expansion of the lesions in MS.

Comparison of clinical findings and pathology of MOGAD in two studies of more than 10 patients.

Reference Takai et al. (33) Höftberger et al. (34)
Clinical findings Patients, n 11 24 (Autopsy 2)
Age (year) 29 (9–64)* 10 (1–66)*
Female/Male (female %) 6/11, 55% 13/22, 59%
Diagnosis ADEM-like: 6/11LE: 3/11CCE: 2/11 ADEM-like: 11/18NMOSD: 1/18Myelitis: 2/18ON: 2/18CCE: 1/18BS: 1/18
Time from attack to biopsy (month) 1 (0.5–96)* 7 (0–516)*
Total follow up period (month) 33 (12–180)* 43 (3–516)*
Pathology Demyelination pattern
Perivenous (ADEM-like) 91% 21%
Confluent (MS-like) 2% 29%
Transitional (perivenous + confluent) 7% 50%
MOG-dominant myelin loss 37% 0%
Astrocytopathy 0/11 (0%) 0/17 (0%)
CD4-dominant T-cell infiltration 10/11 (91%) +
Complement deposition 2/11 (18%) 8/8 (100%)

*Median (range). ADEM, acute demyelinating encephalomyelitis; BS, brain stem lesion; CCE, cortical encephalitis; LE, leukoencephalopathy; NMOSD, neuromyelitis optica spectrum disorders; MOG, myelin oligodendrocyte glycoprotein; MOGAD, MOG antibody-associated disease; MS, multiple sclerosis; ON, optic neuritis.

Summary of the clinical and pathological findings of MOGAD in case reports.

A
Clinical findings Reference
Case Age Sex Clinical phenotype Antibody other than MOG Author
1 49 F Rel.TDL (open ring) nr Konig et al. (35)
2 71 M Blt.ON, MY, multiple brain lesions AQP4 Di Pauli et al. (36)
3 66 F Rel.myelitis + TDL (open ring) - Spadaro et al. (37)
4 63 F CIS - Jarius et al. (38)
5 67 F Rel.LETM + TDL (multiple) - Wang et al. (39)
6 49 M ADEM (MY + multiple brain lesion) nr Körtvélyessy et al. (40)
7 34 M ADEM (MY + multiple brain lesion) nr
8 28 F Blt.ON + TDL (infiltrative) - Zhou et al. (41)
9 25 F ADEM + ON -
10 29 F CCE + Blt.ON - Ikeda et al. (42)
11 46 M CCE + ON - Fujimori et al. (24)
12 47 M ADEM (diffuse) - Komatsu et al. (43)
13 45 M TDL (infiltrative) - Shu et al. (44)
14 6 F TDL (infiltrative) -
15 37 F CCE + MY - Papathanasiou et al. (45)
16 40 M CCE + multiple brain/brain stem lesion P/C-ANCA
17 52 F TDL (lymphoma) - Uzura et al. (46)
18 17 M CCE + ON + MY - Valencia-Sanchez et al. (47)
19 35 F CCE -
B
Pathological findings
Case Material Demyelination pattern Oligodendrocyte Damaged myelin component Astrocytopathy Site of complement deposition IgG deposition Infiltrating inflammatory cells
Astrocyte morphology AQP4-loss Myelin Inside macrophage Perivascular
1 Biopsy (Brain) Nr Nr Nr Nr Nr Nr + Nr Nr M, T
2 Autopsy Confluent Preoligodendrocyte MOG = MBP > CNP ase Loss + Nr Nr + Nr CD3, CD8, low B,
3 Biopsy (Brain) Confluent Preserved MOG > PLP Reactive − + + − Diffuse with fiber M, T (CD8)
4 Biopsy (Brain) Nr Preserved Even Reactive − Nr + Nr Macrophage CD4 = CD8, B
5 Biopsy (Brain) Confluent Nr Nr Reactive Nr Nr Nr Nr Nr M, T, low B
6 Biopsy (Brain) Confluent Apoptosis MAG > MOG Nr Nr + + Nr + M,T (CD8), B
7 Biopsy (Brain) Confluent Preserved Even Nr Nr Nr Nr + Nr M (rim), T dominant, CD8
8 Biopsy (Brain) Confluent Nr Nr Reactive − Nr Nr Nr Nr M, T (CD4), low B
9 Biopsy (Brain)
10 Biopsy (Brain) Perivenous, subpial Preserved MOG > MAG, MBP Reactive − − − − − M, T (CD4 > CD8), low B
11 Biopsy (Brain) No demyelination Nr Nr Nr Nr Nr Nr Nr Nr M, T, B
12 Biopsy (Brain) Perivenous, confluent Preserved MOG > MAG, MBP Reactive − + + − Diffuse M, T (CD4 > CD8), low B
13 Biopsy (Brain) Confluent Preoligodendrocyte Nr Reactive Decrease − Minor − Nr M, T (CD4 > CD8), low B
14 Biopsy (Brain) Confluent Preoligodendrocyte Nr Reactive Decrease − Minor − Nr M, T (CD4 > CD8), low B
15 Biopsy (Brain) Nr Nr Nr Nr Nr Nr Nr Nr Nr M, T, B
16 Biopsy (Brain) Perivenous, confluent Nr Nr Nr Nr Nr Nr Nr Nr T, B
17 Biopsy (Brain) Perivenous, confluent Preserved MOG > MAG, MBP Reactive − − − − Perivenous M, T, low B
18 Biopsy (Brain) Perivenous, subpial Nr even Nr Nr − − − Nr M, T (CD4 > 8)
19 Biopsy (Brain) Subpial Nr Nr Nr Nr Nr Nr Nr Nr M, T (CD4 = 8), B*

(A) ADEM, acute disseminated encephalomyelitis; ANCA, anti-neutrophil cytoplasmic antibody; AQP4, aquaporin 4; Blt., bilateral; CCE, cerebral cortical encephalitis; CIS, clinically isolated syndrome; F, female; LETM, longitudinally extensive transvers myelitis; M, male; MOGAD, myelin oligodendrocyte glycoprotein antibody-associated disease; MY, myelitis; ON, optic neuritis; P/C, perinuclear/cytoplasmic; Rel., relapsing; TDL, tumefactive demyelinating lesion. *, **Same patient in case11* and case7** in reference (33). (B) Nr, not reported; MAG, myelin associated glycoprotein; MOG, myelin oligodendrocyte glycoprotein; MBP, myelin basic protein; CNP, 2′,3’-Cyclic-nucleotide 3′-phosphodiesterase; PLP, Proteolipid protein; M, macrophage; T, T cells; B, B cells. +, present; −, absent. *Focal meningeal B-cell agglutination without features of ectopic B-cell follicles.

Slowly expanding lesion in SPMS. A large well-demarcated demyelinating lesion was seen with peripheral infiltration of myelin phagocytosed macrophages (insert). MBP (blue)/CD68 (brown). MBP, myelin basic protein; SPMS, secondary progressive multiple sclerosis.

 Distribution of demyelinating lesions

Demyelinating lesions in MOGAD patients are found mainly in the white matter but also in the subpial cortex to cortico-medullary junction and deep gray matter (Figure 4) (33, 34, 47). Within these lesions, CD68-positive macrophages/microglia widely infiltrate the cortex (Figure 4). The frequency of cortical demyelination is reported to be higher in MOGAD patients with cerebral involvement than in MS patients (34), which is compatible with the high incidence of cortical involvement in MOGAD patients, evidenced by conditions such as ADEM and cerebral cortical encephalitis (29). In addition, inflammatory cells infiltrate around meningeal vessels adjacent to subpial demyelinating lesions (33, 34, 45, 47). In cerebral cortical encephalitis of MOGAD patients, brain MRI scans often show contrast enhancing effects in the meninges which may reflect such inflammation around the meningeal vessels (47).

Subpial demyelination in MOGAD. (A) Myelin fibers were widely lost in the subpial cortex. Perivenous demyelination was observed at the cortical-medullary junction. (B) CD68 positive macrophages/microglia were diffusely infiltrated the demyelinated cortex. (A) MBP, (B) CD68. MBP, myelin basic protein; MOGAD, myelin oligodendrocyte glycoprotein antibody-associated disease.

 Preferential loss of specific myelin component(s)

When evaluating demyelinating lesions, it is important to identify primarily damaged myelin component(s) by immunohistochemistry to assess the type and stage of the disease (48, 54). Our study and several previous case reports indicated that some demyelinating lesions found in patients with MOGAD showed MOG-dominant myelin loss especially in the early-stage (Figure 5) (33, 37, 42, 46), and some myelin-laden macrophages localized at the perivascular space showed MOG-dominant phagocytosis (33). In addition, oligodendrocytes are relatively preserved in MOGAD demyelinating lesions (33, 37, 38, 44). These findings support that MOGAD actually targets MOG and that its demyelination process may initially occur on the surface of the myelin sheath. However, Höftberger et al. reported no MOG dominant myelin loss in their study (34), and it remains to be clarified what this difference originated from. On the other hand, some reports indicated that preferential loss of myelin associated glycoprotein (MAG) could occur in MOGAD patients although the incidence was very low (34, 40). Since MAG is expressed in the innermost layer of the myelin sheath and is most distant from the oligodendrocyte cell body, preferential loss of MAG is thought to reflect oligodendrocyte damage (distal oligodendrogliopathy) (55). This finding is seen in patients with MS pattern III lesions (56); Balo’s disease (57); AQP4 + NMOSD (58); and ischemic tissue damage such as cerebral infarction (59). Since MOG is also expressed at the surface of oligodendrocytes, depending on the concentration or characteristics of MOG antibodies, some oligodendrocytes may be damaged by MOG antibodies.

Characteristics of demyelinating lesions in MOGAD. (A,B) Loss of MOG staining was more evident than MAG staining. (C) Oligodendrocytes were well preserved in the demyelinating lesion. (D) Axonal enlargement was present, suggesting neuroaxonal alteration but axonal staining was relatively preserved compared to demyelination. (E,F) Activated astrocytes with dense AQP4 staining were observed. (A) MOG, (B) MAG, (C) TPPP, (D) NF, (E) GFAP, (F) AQP4. AQP4, aquaporin 4; GFAP, glial fibrillary acidic protein; MAG, myelin associated glycoprotein; MBP, myelin basic protein; MOG, myelin oligodendrocyte glycoprotein; MOGAD, MOG antibody-associated disease; NF, neurofilament; TPPP, tubulin polymerization promoting proteins.

 Characteristics of inflammatory cell infiltration

The cellular infiltrate in inflammatory demyelinating lesions is composed mainly of myelin phagocytosing macrophages at the sites of demyelination and T-cell clusters in the perivascular space (perivascular cuffing). Infiltrating cells in the lesions of MOGAD are essentially similar (Tables 1, 2), but a characteristic feature of MOGAD is CD4+ T-cell-dominant infiltration in the demyelinating lesions (33, 34), which is different from the dominance of CD8+ T-cell infiltrates in MS lesions (60, 61). Some of those CD4+ T cells in MOGAD might be reactive to MOG epitopes. However, it should be noted that the timing of the sampling of specimens should be considered. In AQP4 + NMOSD, the main subpopulation of T cells infiltrated in the lesions changes from CD4 in the acute phase to CD8 in the chronic phase of the disease (49). Most of the CNS tissue specimens of MOGAD patients examined in the published studies were obtained in the acute phase, and the pathological findings in the chronic phase have not been examined. Therefore, the characteristics of T cells infiltrating the lesion may reflect differences in the stage of the disease rather than pathogenesis, and further detailed verification is required in the future. However, it is known that the levels of T helper 17 (Th17)-related cytokines are markedly elevated in the cerebrospinal fluid (CSF) of patients during the acute phase of MOGAD and AQP4 + NMOSD when compared with those of MS patients and control subjects (62). Thus, in the acute phase, T-cell subpopulations infiltrating the lesions are different between MOGAD and MS patients.

B cells are seen in small numbers in the perivascular space, but are less frequent than T cells (33, 34). Additionally, ectopic lymphoid follicles, as reported in MS (63, 64), have not been detected in MOGAD patients. However, occasionally B-cell aggregates may be seen in the leptomeninges (47). In MOGAD patients, intrathecal production of MOG antibodies seems to occur more frequently than in AQP4 + NMOSD patients (65–68), suggesting that B cells infiltrating the CNS produce MOG antibodies and contribute to the pathogenesis of the disease. In addition, CXCR4 is upregulated in B cells in patients with MOGAD (69), and its ligand, CXCL12, is known to be elevated in the CSF (70). Thus, CXCL12/CXCR4 may contribute to the chemotaxis of B cells and other inflammatory cells in MOGAD patients (71).

 Deposition of humoral immunity and complement activity

Since MOG antibodies are mainly composed of those in the IgG1 subclass (27, 72), complement-mediated cytotoxicity (CDC) has been considered to contribute to the pathogenesis of MOGAD. In fact, both in vitro and in vivo, it has been reported that MOG antibody-induced cytotoxicity and demyelination can occur in a complement-mediated manner (72–74). Indeed, some previous case reports on biopsied brain lesions in MOGAD patients showed the deposition of complement components on myelin fibers and myelin debris phagocytosed by macrophages, and the authors concluded that the lesions were probably caused by humoral immune-mediated demyelination, such as MS pattern II lesions (37, 38, 40, 56). This type of MS lesion is histologically characterized by extensive confluent demyelination with tissue deposition of humoral immune factors such as complements and immunoglobulins (22). However, the histopathological findings of complements in MOGAD patients remain debatable, as the reported results have been inconsistent (33, 34). In our study, only 2 of 11 MOGAD patients showed tissue deposition of complement, which was much less frequent and dense than in AQP4 + NMOSD patients with perivascular deposition of activated complements (C9neo) in all acute lesions (33). However, Höftberger et al. concluded that active complement deposition was observed in all 8 patients they evaluated (34) (Table 2). This difference may be due to the clinical severity, timing of tissue sampling or inter-individual variability in the severity of MOG-IgG-related cytotoxicity other than complement activation, such as antibody-dependent cellular phagocytosis (ADCP) and antibody-dependent cellular cytotoxicity (ADCC) (75, 76). However, a recent in vitro study demonstrated that MOG antibodies elicited much less complement activation than AQP4 antibodies (77). AQP4 has two isoforms, M1 and M23, that differ in their transcription start sites (78). AQP4-M1 and M23 are coexpressed in the CNS, and M23 is known to form large well-ordered assemblies called orthogonal arrays of particles (OAPs) (78) and is reported to be more highly expressed in the optic nerve and spinal cord, where NMOSD lesions are more likely to occur (79). The formation of OAPs allows AQP4 to be densely expressed on the cell surface, facilitating AQP4 antibody clustering on the cell membrane. The classical complement activation pathway is initiated by the binding of C1q to the Fc portion of IgG, but requires bivalent or multivalent binding (80). Thus, complement components are more likely to be activated when IgG is densely bound on the plasma membrane, and in fact, the presence of OAPs significantly enhanced complement-mediated cytotoxicity by the presence of AQP4 antibodies (81). On the other hand, MOG constitutes a quantitatively minor component (0·05%) of the myelin sheath (1), and MOG antibodies require bivalent binding when binding to MOG, making it difficult for them to assemble on the cell membrane, and resulting in low C1q binding ability (82). It is necessary to study in detail whether the amount and characteristics of MOG antibodies affect the degree of complement activation following binding to AQP4.

 Comparison between MOGAD and MS

The dominant pattern of demyelinating lesions (perivenous demyelination) in MOGAD is similar to that of ADEM rather than MS. The characteristics of infiltrating T cells also differ in MOGAD and MS, as noted above (Table 3). However, we cannot rule out the possibility that some patients with MOGAD may have a pathology similar to MS since previous studies on MOG-EAE have demonstrated that the ratios of myelin antigen-specific lymphocytes and autoantibodies to myelin could influence the dominance of perivenous or confluent demyelination (8, 85). Additionally, there is a report that MOG antibodies purified from two MOGAD patients (whose MOG antibodies were capable of binding to rodent MOG) and administered intrathecally to EAE subjects induced by MOG-specific T cells did not produce demyelinating lesions with deposition of activated complement, but in the presence of MBP-specific T cells, demyelinating lesions similar to MS pattern II developed (86). These findings suggested that T cells in some cases of MOGAD may recognize myelin protein(s) other than MOG and activate complements. Thus, further investigations are needed to confirm whether this is the case in the human pathology of MOGAD. However, it should be noted that MS Pattern II is a pathological classification proposed before the discovery of conformation-sensitive MOG antibodies and includes many brain biopsy samples from cases with atypical or fulminant cerebral lesions for MS (56). Jarius et al. found that only one of the 13 cases with MS Pattern II pathology was positive for MOG antibodies and suggested its limited involvement (38). Therefore, it may include other inflammatory demyelinating pathologies than MS and MOGAD and require further verification.

Comparison of the major pathological findings of acute lesions in MOGAD, MS, and AQP4 + NMOSD.

Disease MOGAD MS AQP4 + NMOSD
Primary target Myelin > Oligodendrocyte Myelin, Oligodendrocyte Astrocyte
Histopathology
Lesion distribution Mainly in WM, the cerebral cortex and deep GM can also be involved Mainly in periventricular and juxtacortical WM, (cerebral cortex in the progressive phase) Both WM and GM, mainly in the spinal cord and optic nerves
Pattern of demyelination Perivenous > Confluent or Transitional* Confluent (SEL in the progressive phase) Secondary in the astrocyte lytic lesions, Distal oligodendrogliopathy
Lesion edge Ill-defined ~ sharply defined Sharply defined Sharply defined
Damaged myelin proteins MOG > or = others MAG > others (in Pattern III) or Even (in the other patterns) MAG > others
Oligodendrocyte Relatively preserved Partially loss ~ regenerate Loss
Astrocyte Reactive Reactive Loss
AQP4-loss None ~ Mild None ~ Mild Severe
Axon Preserved Relatively preserved, (degenerated in the progressive phase) Damaged in various degrees
Site of complement deposition Myelin, inside macrophage Myelin, inside macrophage (in MS Pattern II) Vasculocentric (rim/rosette pattern)
Cellular infiltration
Macrophage Most conspicuous in the PVS and parenchyma Most conspicuous in parenchyma, especially at the lesion edge Most conspicuous in the PVS and parenchyma
T cells CD4 dominant in the PVS CD8 dominant in the PVS CD4 dominant in the PVS(CD8 dominant in the chronic phase)
B cells A small number in the PVS, occasional aggregates in the leptomeninges A small number in the PVS (Ectopic lymphoid follicles in the progressive phase) A small number in the PVS
Neutrophil/Eosinophil Mild ~ Moderate Rare Mild ~ Marked
Fluid pathology
Cell damage marker MBP elevated, GFAP not elevated MBP elevated, GFAP not elevated (elevated in the progressive phase) (83, 84) MBP elevated, GFAP remarkably elevated
Cytokine profile Marked elevation of Th17-related cytokines relative to MS Marked elevation of Th17-related cytokines relative to MS

AQP4, aquaporin 4; GFAP, glial fibrillary acidic protein; GM, gray matter; MAG, myelin associated glycoprotein; MBP, myelin basic protein; MOG, myelin oligodendrocyte glycoprotein; MOGAD, MOG antibody-associated disease; MS, multiple sclerosis; NMOSD, neuromyelitis optica spectrum disorders; PVS, perivascular space; SEL, slowly expanding lesion; WM, white matter. *Perivenous + Confluent.

 Comparison between MOGAD and AQP4 + NMOSD

The fundamental difference in the pathologies of the two diseases is that the main target of immune attack is myelin in MOGAD but is astrocytes in AQP4 + NMOSD (62). In previous pathological studies of MOGAD, there has been no astrocytic damage except in patient doubly positive for AQP4 and MOG antibodies (36). In the demyelinating lesions in MOGAD, astrocytes are essentially activated and AQP4 is also strongly stained on immunohistochemistry images (Figure 5), although two cases of partially decreased AQP4 expression in MOGAD with tumefactive brain lesions have been reported (Table 2) (44). The pathological process starts in the perivascular regions in both MOGAD and AQP4 + NMOSD, but they show distinct features of demyelinating lesions: in MOGAD, MOG is predominantly lost with relatively preserved oligodendrocytes, whereas in AQP4 + NMOSD, MAG is preferentially damaged, and oligodendrocytes are lost, but MOG is relatively preserved (Figure 6). The immunohistochemical staining pattern of activated complement deposition also differs: a rosette-like staining around blood vessels is seen in AQP4 + NMOSD (49, 87, 88), while in MOGAD, perivascular complement deposition is much less (Figure 7) but stained on myelinated fibers and in myelin degradation products within macrophages (Figure 7; Tables 2, 3) (37, 38, 40). Despite these different patterns of demyelination, MOGAD and AQP4 + NMOSD share some clinical features, such as optic neuritis and longitudinally extensive myelitis (18, 89), and cytokine profiles (upregulation of Th17-related cytokines) in the CSF (62) as autoantibody-associated CNS diseases.

Characteristics of astrocytopathic lesions in AQP4 + NMOSD. (A,B) Loss of MAG staining was more evident than MOG staining. (C) Numerous oligodendrocytes were lost in the lesion. (D) Axonal enlargement was present, suggesting neuroaxonal alteration, but axonal staining was relatively preserved compared to demyelination and astrocyte loss. (D–F) Astrocytes were almost completely lost in the lesion. (A) MOG, (B) MAG, (C) TPPP, (D) NF, (E) GFAP, (F) AQP4. AQP4: aquaporin 4, GFAP, glial fibrillary acidic protein; MAG, myelin associated glycoprotein; MBP, myelin basic protein; MOG, myelin oligodendrocyte glycoprotein; MOGAD, MOG antibody-associated disease; NF, neurofilament; NMOSD, neuromyelitis optica spectrum disorders; TPPP, tubulin polymerization promoting proteins.

Comparison of the deposition pattern of activated complements in MOGAD and AQP4 + NMOSD. (A) Only mild perivascular depositions of complements were seen in MOGAD even in the active lesion where perivascular cuffing was evident. (B,C) In active demyelinating lesions, complement staining was detected on myelin debris phagocytosed by macrophages (red arrow). (D) Multiple rosette-like stainings of complement deposition were seen in the NMOSD lesion. (D–F) Perivascular complement depositions were seen within AQP4-loss lesions. (A,C,D,F) C9neo. (B) MBP/CD68, (E) AQP4. AQP4, aquaporin 4; MBP, myelin basic protein; MOGAD, myelin oligodendrocyte glycoprotein antibody-associated disease; NMOSD, neuromyelitis optica spectrum disorders.

 Conclusion

Recently, the international diagnostic criteria for MOGAD have been proposed (29), and certain pathological features of the disease have been clarified (29), indicating that MOGAD is a disease entity distinct from MS and AQP4 + NMOSD. In fact, published articles on MOGAD have been rapidly increasing in recent years, and a few international clinical trials for relapsing MOGAD have already begun.

Considering the currently available data of the histopathological studies of MOGAD and some basic research with MOG antibodies, the immunopathological process in MOGAD may be summarized as follows. Initially, the breakdown of immune tolerance leads to the generation of MOG-reactive T cells that stimulate the production of MOG antibodies from B cells in the periphery. Triggered by infection, vaccination, or other stimuli, these MOG-reactive T cells are activated and penetrate the blood–brain barrier (BBB) into the CNS and aggregate at the perivascular space of the meninges and parenchyma (perivascular cuffing). MOG antigens in the CNS further activate these cells which are primarily CD4-positive T cells and promote a Th17-dominant cytokine milieu in the CNS and the BBB disruption. As a result, more MOG antibodies enter the CNS. Then the autoantibodies target myelins, especially MOG, to demyelinate the nerve fibers from the surface of myelin sheath via CDC (noted as deposition of activated complements), ADCC (in cooperation with infiltrating granulocytes), ADCP (seen as myelin phagocytosed macrophages), and other mechanisms. A fraction of the demyelinating lesions may exhibit MOG-dominant loss, suggesting a MOG-targeted pathology, and some oligodendrocytes may also be damaged. But compared to the remarkable CDC to cause astrocytolysis in AQP4 + NMOSD, the pathological role of CDC for demyelination may be less in some cases of MOGAD. These events probably occur simultaneously around multiple blood vessels (perivenous demyelination) in the white and gray matters. Subsequently, broken MOG and other myelin components are phagocytosed by macrophages (myelin-laden macrophages in the parenchyma and perivascular space), further enhancing antigen presentation and activating MOG-reactive CD4-positive T cells that induce the activation and infiltration of cytotoxic effector T cells against myelins and B cells that produce MOG antibodies intrathecally. These cellular and humoral immune responses are augmented through the interaction with proinflammatory cytokines/chemokines, which further exacerbates the disease state resulting in fusion of the lesions to form extensive demyelination (confluent demyelination). This confluent demyelination in MOGAD may develop by a different mechanism from that of the radial expansion of MS lesions.

However, we should investigate further details of the pathophysiology of MOGAD by means of various technologies including molecular immunology, omics, advanced imaging, neurophysiological tests, therapeutic response and artificial intelligence as well as conventional histopathological analyses. Furthermore, the histopathological studies in MOGAD to date have been derived from brain biopsies, and we should clarify whether the lesion characteristics are similar in other CNS regions, such as the optic nerve and spinal cord. Studies on how differences in the histopathologic findings may affect the severity and clinical phenotype in patients with MOGAD are also needed. These studies are expected to contribute to a better understanding and management of MOGAD.

 Author contributions

YT, KF, and MA contributed to conception and design of the study. YT and TM organized the database. YT wrote the first draft of the manuscript, tables, and figures. All authors contributed to manuscript revision, read, and approved the submitted version.

 Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

 Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

 References Johns TG Bernard CC. The structure and function of myelin oligodendrocyte glycoprotein. J Neurochem. (1999) 72:1–9. doi: 10.1046/j.1471-4159.1999.0720001.x Boyle LH Traherne JA Plotnek G Ward R Trowsdale J. Splice variation in the cytoplasmic domains of myelin oligodendrocyte glycoprotein affects its cellular localisation and transport. J Neurochem. (2007) 102:1853–62. doi: 10.1111/j.1471-4159.2007.04687.x, PMID: 17573820 Delarasse C Della Gaspera B Lu CW Lachapelle F Gelot A Rodriguez D . Complex alternative splicing of the myelin oligodendrocyte glycoprotein gene is unique to human and non-human primates. J Neurochem. (2006) 98:1707–17. doi: 10.1111/j.1471-4159.2006.04053.x, PMID: 16903876 Pham-Dinh D Mattei MG Nussbaum JL Roussel G Pontarotti P Roeckel N . Myelin/oligodendrocyte glycoprotein is a member of a subset of the immunoglobulin superfamily encoded within the major histocompatibility complex. Proc Natl Acad Sci U S A. (1993) 90:7990–4. doi: 10.1073/pnas.90.17.7990 Lebar R Lubetzki C Vincent C Lombrail P Boutry JM. The M2 autoantigen of central nervous system myelin, a glycoprotein present in oligodendrocyte membrane. Clin Exp Immunol. (1986) 66:423–34. PMID: 2434274 Linington C Lassmann H. Antibody responses in chronic relapsing experimental allergic encephalomyelitis: correlation of serum demyelinating activity with antibody titre to the myelin/oligodendrocyte glycoprotein (MOG). J Neuroimmunol. (1987) 17:61–9. doi: 10.1016/0165-5728(87)90031-2, PMID: 2445777 Schluesener HJ Sobel RA Linington C Weiner HL. A monoclonal antibody against a myelin oligodendrocyte glycoprotein induces relapses and demyelination in central nervous system autoimmune disease. J Immunol. (1987) 139:4016–21. doi: 10.4049/jimmunol.139.12.4016, PMID: 3500978 Linington C Bradl M Lassmann H Brunner C Vass K. Augmentation of demyelination in rat acute allergic encephalomyelitis by circulating mouse monoclonal antibodies directed against a myelin/oligodendrocyte glycoprotein. Am J Pathol. (1988) 130:443–54. PMID: 2450462 Lebar R Baudrimont M Vincent C. Chronic experimental autoimmune encephalomyelitis in the Guinea pig. Presence of anti-M2 antibodies in central nervous system tissue and the possible role of M2 autoantigen in the induction of the disease. J Autoimmun. (1989) 2:115–32. doi: 10.1016/0896-8411(89)90149-2, PMID: 2765095 Bittner S Afzali AM Wiendl H Meuth SG. Myelin oligodendrocyte glycoprotein (MOG35-55) induced experimental autoimmune encephalomyelitis (EAE) in C57BL/6 mice. J Visual Exp. (2014) 15:51275. doi: 10.3791/51275-v Lassmann H Bradl M. Multiple sclerosis: experimental models and reality. Acta Neuropathol. (2017) 133:223–44. doi: 10.1007/s00401-016-1631-4, PMID: 27766432 Lassmann H. The changing concepts in the neuropathology of acquired demyelinating central nervous system disorders. Curr Opin Neurol. (2019) 32:313–9. doi: 10.1097/WCO.0000000000000685, PMID: 30893100 Lampasona V Franciotta D Furlan R Zanaboni S Fazio R Bonifacio E . Similar low frequency of anti-MOG IgG and IgM in MS patients and healthy subjects. Neurology. (2004) 62:2092–4. doi: 10.1212/01.WNL.0000127615.15768.AE, PMID: 15184621 Reindl M Schanda K Woodhall M Tea F Ramanathan S Sagen J . International multicenter examination of MOG antibody assays. Neurol Neuroimmunol Neuroinflamm. (2020) 7:674. doi: 10.1212/NXI.0000000000000674 Gastaldi M Scaranzin S Jarius S Wildeman B Zardini E Mallucci G . Cell-based assays for the detection of MOG antibodies: a comparative study. J Neurol. (2020) 267:3555–64. doi: 10.1007/s00415-020-10024-0, PMID: 32623596 Waters PJ Komorowski L Woodhall M Lederer S Majed M Fryer J . A multicenter comparison of MOG-IgG cell-based assays. Neurology. (2019) 92:e1255. doi: 10.1212/WNL.0000000000007096 Kitley J Woodhall M Waters P Leite MI Devenney E Craig J . Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype. Neurology. (2012) 79:1273–7. doi: 10.1212/WNL.0b013e31826aac4e Sato DK Callegaro D Lana-Peixoto MA Waters PJ de Haidar Jorge FM Takahashi T . Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders. Neurology. (2014) 82:474–81. doi: 10.1212/WNL.0000000000000101, PMID: 24415568 Misu T Sato DK Nakashima I Fujihara K. MOG-IgG serological status matters in paediatric ADEM. J Neurol Neurosurg Psychiatry. (2015) 86:242. doi: 10.1136/jnnp-2014-308723, PMID: 25136054 Di Pauli F Mader S Rostasy K Schanda K Bajer-Kornek B Ehling R . Temporal dynamics of anti-MOG antibodies in CNS demyelinating diseases. Clin Immunol. (2011) 138:247–54. doi: 10.1016/j.clim.2010.11.013, PMID: 21169067 Matsumoto Y Misu T Mugikura S Takai Y Nishiyama S Kuroda H . Distinctive lesions of brain MRI between MOG-antibody-associated and AQP4-antibody-associated diseases. J Neurol Neurosurg Psychiatry. (2020) 92:682–4. doi: 10.1136/jnnp-2020-324818 Jurynczyk M Geraldes R Probert F Woodhall MR Waters P Tackley G . Distinct brain imaging characteristics of autoantibody-mediated CNS conditions and multiple sclerosis. Brain. (2017) 140:617–27. doi: 10.1093/brain/aww350, PMID: 28364548 Banks SA Morris PP Chen JJ Pittock SJ Sechi E Kunchok A . Brainstem and cerebellar involvement in MOG-IgG-associated disorder versus aquaporin-4-IgG and MS. J Neurol Neurosurg Psychiatry. (2020) 92:384–90. doi: 10.1136/jnnp-2020-325121 Fujimori J Takai Y Nakashima I Sato DK Takahashi T Kaneko K . Bilateral frontal cortex encephalitis and paraparesis in a patient with anti-MOG antibodies. J Neurol Neurosurg Psychiatry. (2017) 88:534–6. doi: 10.1136/jnnp-2016-315094, PMID: 28209651 Ogawa R Nakashima I Takahashi T Kaneko K Akaishi T Takai Y . MOG antibody-positive, benign, unilateral, cerebral cortical encephalitis with epilepsy. Neurol Neuroimmunol Neuroinflamm. (2017) 4:e322. doi: 10.1212/NXI.0000000000000322 Budhram A Mirian A Le C Hosseini-Moghaddam SM Sharma M Nicolle MW. Unilateral cortical FLAIR-hyperintense lesions in anti-MOG-associated encephalitis with seizures (FLAMES): characterization of a distinct clinico-radiographic syndrome. J Neurol. (2019) 266:2481–7. doi: 10.1007/s00415-019-09440-8 Waters P Woodhall M O'Connor KC Reindl M Lang B Sato DK . MOG cell-based assay detects non-MS patients with inflammatory neurologic disease. Neurol Neuroimmunol Neuroinflamm. (2015) 2:e89. doi: 10.1212/NXI.0000000000000089, PMID: 25821844 Ketelslegers IA Van Pelt DE Bryde S Neuteboom RF Catsman-Berrevoets CE Hamann D . Anti-MOG antibodies plead against MS diagnosis in an acquired demyelinating syndromes cohort. Mult Scler. (2015) 21:1513–20. doi: 10.1177/1352458514566666, PMID: 25662345 Banwell B Bennett JL Marignier R Kim HJ Brilot F Flanagan EP . Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: international MOGAD panel proposed criteria. Lancet Neurol. (2023) 22:268–82. doi: 10.1016/S1474-4422(22)00431-8, PMID: 36706773 Popescu BF Lucchinetti CF. Pathology of demyelinating diseases. Annu Rev Pathol. (2012) 7:185–217. doi: 10.1146/annurev-pathol-011811-132443 Lucchinetti CF. Multiple sclerosis and the spectrum of CNS inflammatory demyelinating diseases. Semin Neurol. (2008) 28:003–6. doi: 10.1055/s-2007-1019123 Young NP Weinshenker BG Parisi JE Scheithauer B Giannini C Roemer SF . Perivenous demyelination: association with clinically defined acute disseminated encephalomyelitis and comparison with pathologically confirmed multiple sclerosis. Brain. (2010) 133:333–48. doi: 10.1093/brain/awp321, PMID: 20129932 Takai Y Misu T Kaneko K Chihara N Narikawa K Tsuchida S . Myelin oligodendrocyte glycoprotein antibody-associated disease: an immunopathological study. Brain. (2020) 143:1431–46. doi: 10.1093/brain/awaa102, PMID: 32412053 Hoftberger R Guo Y Flanagan EP Lopez-Chiriboga AS Endmayr V Hochmeister S . The pathology of central nervous system inflammatory demyelinating disease accompanying myelin oligodendrocyte glycoprotein autoantibody. Acta Neuropathol. (2020) 139:875–92. doi: 10.1007/s00401-020-02132-y, PMID: 32048003 Konig FB Wildemann B Nessler S Zhou D Hemmer B Metz I . Persistence of immunopathological and radiological traits in multiple sclerosis. Arch Neurol. (2008) 65:1527–32. doi: 10.1001/archneur.65.11.1527, PMID: 19001173 Di Pauli F Hoftberger R Reindl M Beer R Rhomberg P Schanda K . Fulminant demyelinating encephalomyelitis: insights from antibody studies and neuropathology. Neurol Neuroimmunol Neuroinflamm. (2015) 2:e175. doi: 10.1212/NXI.0000000000000175, PMID: 26587556 Spadaro M Gerdes LA Mayer MC Ertl-Wagner B Laurent S Krumbholz M . Histopathology and clinical course of MOG-antibody-associated encephalomyelitis. Ann Clin Translat Neurol. (2015) 2:295–301. doi: 10.1002/acn3.164, PMID: 25815356 Jarius S Metz I Konig FB Ruprecht K Reindl M Paul F . Screening for MOG-IgG and 27 other anti-glial and anti-neuronal autoantibodies in 'pattern II multiple sclerosis' and brain biopsy findings in a MOG-IgG-positive case. Mult Scler. (2016) 22:1541–9. doi: 10.1177/1352458515622986, PMID: 26869529 Wang JJ Jaunmuktane Z Mummery C Brandner S Leary S Trip SA. Inflammatory demyelination without astrocyte loss in MOG antibody-positive NMOSD. Neurology. (2016) 87:229–31. doi: 10.1212/WNL.0000000000002844, PMID: 27306633 Kortvelyessy P Breu M Pawlitzki M Metz I Heinze HJ Matzke M . ADEM-like presentation, anti-MOG antibodies, and MS pathology: TWO case reports. Neurol Neuroimmunol Neuroinflamm. (2017) 4:e335. doi: 10.1212/NXI.0000000000000335, PMID: 28331892 Zhou L Huang Y Li H Fan J Zhangbao J Yu H . MOG-antibody associated demyelinating disease of the CNS: a clinical and pathological study in Chinese Han patients. J Neuroimmunol. (2017) 305:19–28. doi: 10.1016/j.jneuroim.2017.01.007, PMID: 28284341 Ikeda T Yamada K Ogawa R Takai Y Kaneko K Misu T . The pathological features of MOG antibody-positive cerebral cortical encephalitis as a new spectrum associated with MOG antibodies: a case report. J Neurol Sci. (2018) 392:113–5. doi: 10.1016/j.jns.2018.06.028 Komatsu T Matsushima S Kaneko K Fukuda T. Perivascular enhancement in anti-MOG antibody demyelinating disease of the CNS. J Neurol Neurosurg Psychiatry. (2019) 90:111–2. doi: 10.1136/jnnp-2018-319235, PMID: 30297517 Shu Y Long Y Wang S Hu W Zhou J Xu H . Brain histopathological study and prognosis in MOG antibody-associated demyelinating pseudotumor. Ann Clin Transl Neurol. (2019) 6:392–6. doi: 10.1002/acn3.712, PMID: 30847372 Papathanasiou A Tanasescu R Davis J Rocha MF Singhal S O'Donoghue MF . MOG-IgG-associated demyelination: focus on atypical features, brain histopathology and concomitant autoimmunity. J Neurol. (2020) 267:359–68. doi: 10.1007/s00415-019-09586-5 Uzura Y Takeuchi H Ashida S Fujii C Shishido-Hara Y Inaba T . A tumefactive anti-MOG antibody associated disorder heralding central nervous system B-cell lymphoma: case report on diagnostic challenge. J Neuroimmunol. (2022) 365:577823. doi: 10.1016/j.jneuroim.2022.577823 Valencia-Sanchez C Guo Y Krecke KN Chen JJ Redenbaugh V Montalvo M . Cerebral cortical encephalitis in myelin oligodendrocyte glycoprotein antibody-associated disease. Ann Neurol. (2023) 93:297–302. doi: 10.1002/ana.26549 Kuhlmann T Ludwin S Prat A Antel J Brück W Lassmann H. An updated histological classification system for multiple sclerosis lesions. Acta Neuropathol. (2017) 133:13–24. doi: 10.1007/s00401-016-1653-y, PMID: 27988845 Takai Y Misu T Suzuki H Takahashi T Okada H Tanaka S . Staging of astrocytopathy and complement activation in neuromyelitis optica spectrum disorders. Brain. (2021) 144:2401–15. doi: 10.1093/brain/awab102, PMID: 33711152 Dal-Bianco A Grabner G Kronnerwetter C Weber M Kornek B Kasprian G . Long-term evolution of multiple sclerosis iron rim lesions in 7 T MRI. Brain. (2021) 144:833–47. doi: 10.1093/brain/awaa436, PMID: 33484118 Prineas JW Kwon EE Cho ES Sharer LR Barnett MH Oleszak EL . Immunopathology of secondary-progressive multiple sclerosis. Ann Neurol. (2001) 50:646–57. doi: 10.1002/ana.1255 Luchetti S Fransen NL van Eden CG Ramaglia V Mason M Huitinga I. Progressive multiple sclerosis patients show substantial lesion activity that correlates with clinical disease severity and sex: a retrospective autopsy cohort analysis. Acta Neuropathol. (2018) 135:511–28. doi: 10.1007/s00401-018-1818-y, PMID: 29441412 Frischer JM Weigand SD Guo Y Kale N Parisi JE Pirko I . Clinical and pathological insights into the dynamic nature of the white matter multiple sclerosis plaque. Ann Neurol. (2015) 78:710–21. doi: 10.1002/ana.24497, PMID: 26239536 Lassmann H Raine CS Antel J Prineas JW. Immunopathology of multiple sclerosis: report on an international meeting held at the Institute of Neurology of the University of Vienna. J Neuroimmunol. (1998) 86:213–7. doi: 10.1016/S0165-5728(98)00031-9, PMID: 9663568 Lassmann H Brück W Lucchinetti C. Heterogeneity of multiple sclerosis pathogenesis: implications for diagnosis and therapy. Trends Mol Med. (2001) 7:115–21. doi: 10.1016/S1471-4914(00)01909-2, PMID: 11286782 Lucchinetti C Bruck W Parisi J Scheithauer B Rodriguez M Lassmann H. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol. (2000) 47:707–17. doi: 10.1002/1531-8249(200006)47:6<707::AID-ANA3>3.0.CO;2-Q, PMID: 10852536 Stadelmann C Ludwin S Tabira T Guseo A Lucchinetti CF Leel-Ossy L . Tissue preconditioning may explain concentric lesions in Balo's type of multiple sclerosis. Brain. (2005) 128:979–87. doi: 10.1093/brain/awh457, PMID: 15774507 Bruck W Popescu B Lucchinetti CF Markovic-Plese S Gold R Thal DR . Neuromyelitis optica lesions may inform multiple sclerosis heterogeneity debate. Ann Neurol. (2012) 72:385–94. doi: 10.1002/ana.23621, PMID: 23034911 Aboul-Enein F Rauschka H Kornek B Stadelmann C Stefferl A Bruck W . Preferential loss of myelin-associated glycoprotein reflects hypoxia-like white matter damage in stroke and inflammatory brain diseases. J Neuropathol Exp Neurol. (2003) 62:25–33. doi: 10.1093/jnen/62.1.25, PMID: 12528815 Hohlfeld R Dornmair K Meinl E Wekerle H. The search for the target antigens of multiple sclerosis, part 2: CD8+ T cells, B cells, and antibodies in the focus of reverse-translational research. Lancet Neurol. (2016) 15:317–31. doi: 10.1016/S1474-4422(15)00313-0, PMID: 26724102 Machado-Santos J Saji E Troscher AR Paunovic M Liblau R Gabriely G . The compartmentalized inflammatory response in the multiple sclerosis brain is composed of tissue-resident CD8+ T lymphocytes and B cells. Brain. (2018) 141:2066–82. doi: 10.1093/brain/awy151, PMID: 29873694 Kaneko K Sato DK Nakashima I Nishiyama S Tanaka S Marignier R . Myelin injury without astrocytopathy in neuroinflammatory disorders with MOG antibodies. J Neurol Neurosurg Psychiatry. (2016) 87:1257–9. doi: 10.1136/jnnp-2015-312676, PMID: 26800711 Magliozzi R Howell O Vora A Serafini B Nicholas R Puopolo M . Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain. (2007) 130:1089–104. doi: 10.1093/brain/awm038 PMID: 17438020 Howell OW Reeves CA Nicholas R Carassiti D Radotra B Gentleman SM . Meningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis. Brain. (2011) 134:2755–71. doi: 10.1093/brain/awr182 Akaishi T Takahashi T Misu T Kaneko K Takai Y Nishiyama S . Difference in the source of anti-AQP4-IgG and anti-MOG-IgG antibodies in CSF in patients with Neuromyelitis Optica Spectrum disorder. Neurology. (2021) 97:e1–e12. doi: 10.1212/WNL.0000000000012175, PMID: 33980704 Matsumoto Y Kaneko K Takahashi T Takai Y Namatame C Kuroda H . Diagnostic implications of MOG-IgG detection in sera and cerebrospinal fluids. Brain. (2023). doi: 10.1093/brain/awad122, PMID: 37061817 Kwon YN Kim B Kim JS Mo H Choi K Oh SI . Myelin oligodendrocyte glycoprotein-immunoglobulin G in the CSF: clinical implication of testing and association with disability. Neurol Neuroimmunol Neuroinflamm. (2022) 9:1095. doi: 10.1212/NXI.0000000000001095 Mariotto S Gajofatto A Batzu L Delogu R Sechi G Leoni S . Relevance of antibodies to myelin oligodendrocyte glycoprotein in CSF of seronegative cases. Neurology. (2019) 93:e1867–72. doi: 10.1212/WNL.0000000000008479, PMID: 31645473 Liu J Yang X Pan J Wei Z Liu P Chen M . Single-Cell transcriptome profiling unravels distinct peripheral blood immune Cell signatures of RRMS and MOG antibody-associated disease. Front Neurol. (2021) 12:807646. doi: 10.3389/fneur.2021.807646 Kothur K Wienholt L Tantsis EM Earl J Bandodkar S Prelog K . Th17, and neutrophil related cerebrospinal fluid cytokine/chemokines are elevated in MOG antibody associated demyelination. PLoS One. (2016) 11:e0149411. doi: 10.1371/journal.pone.0149411, PMID: 26919719 Corbali O Chitnis T. Pathophysiology of myelin oligodendrocyte glycoprotein antibody disease. Front Neurol. (2023) 14:1137998. doi: 10.3389/fneur.2023.1137998, PMID: 36925938 Mader S Gredler V Schanda K Rostasy K Dujmovic I Pfaller K . Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders. J Neuroinflammation. (2011) 8:184. doi: 10.1186/1742-2094-8-184, PMID: 22204662 Peschl P Schanda K Zeka B Given K Bohm D Ruprecht K . Human antibodies against the myelin oligodendrocyte glycoprotein can cause complement-dependent demyelination. J Neuroinflammation. (2017) 14:208. doi: 10.1186/s12974-017-0984-5, PMID: 29070051 Kohyama K Nishida H Kaneko K Misu T Nakashima I Sakuma H. Complement-dependent cytotoxicity of human autoantibodies against myelin oligodendrocyte glycoprotein. Front Neurosci. (2023) 17:1014071. doi: 10.3389/fnins.2023.1014071, PMID: 36816137 Yandamuri SS Filipek B Obaid AH Lele N Thurman JM Makhani N . MOGAD patient autoantibodies induce complement, phagocytosis, and cellular cytotoxicity. JCI Insight. (2023) 8:5373. doi: 10.1172/jci.insight.165373, PMID: 37097758 Mader S Ho S Wong HK Baier S Winklmeier S Riemer C . Dissection of complement and fc-receptor-mediated pathomechanisms of autoantibodies to myelin oligodendrocyte glycoprotein. Proc Natl Acad Sci U S A. (2023) 120:e2300648120. doi: 10.1073/pnas.2300648120, PMID: 36943883 Lerch M Schanda K Lafon E Würzner R Mariotto S Dinoto A . More efficient complement activation by anti-Aquaporin-4 compared with anti-myelin oligodendrocyte glycoprotein antibodies. Neurol Neuroimmunol Neuroinflamm. (2023) 10:59. doi: 10.1212/NXI.0000000000200059 Furman CS Gorelick-Feldman DA Davidson KG Yasumura T Neely JD Agre P . Aquaporin-4 square array assembly: opposing actions of M1 and M23 isoforms. Proc Natl Acad Sci U S A. (2003) 100:13609–14. doi: 10.1073/pnas.2235843100, PMID: 14597700 Matiello M Schaefer-Klein J Sun D Weinshenker BG. Aquaporin 4 expression and tissue susceptibility to neuromyelitis optica. JAMA Neurol. (2013) 70:1118–25. doi: 10.1001/jamaneurol.2013.3124, PMID: 23857303 Schumaker VN Hanson DC Kilchherr E Phillips ML Poon PH. A molecular mechanism for the activation of the first component of complement by immune complexes. Mol Immunol. (1986) 23:557–65. doi: 10.1016/0161-5890(86)90119-7, PMID: 3018553 Phuan PW Ratelade J Rossi A Tradtrantip L Verkman AS. Complement-dependent cytotoxicity in neuromyelitis optica requires aquaporin-4 protein assembly in orthogonal arrays. J Biol Chem. (2012) 287:13829–39. doi: 10.1074/jbc.M112.344325, PMID: 22393049 Macrini C Gerhards R Winklmeier S Bergmann L Mader S Spadaro M . Features of MOG required for recognition by patients with MOG antibody-associated disorders. Brain. (2021) 144:2375–89. doi: 10.1093/brain/awab105, PMID: 33704436 Abdelhak A Huss A Kassubek J Tumani H Otto M. Serum GFAP as a biomarker for disease severity in multiple sclerosis. Sci Rep. (2018) 8:14798. doi: 10.1038/s41598-018-33158-8, PMID: 30287870 Barro C Healy BC Liu Y Saxena S Paul A Polgar-Turcsanyi M . Serum GFAP and NfL levels differentiate subsequent progression and disease activity in patients with progressive multiple sclerosis. Neurol Neuroimmunol Neuroinflamm. (2023) 10:52. doi: 10.1212/NXI.0000000000200052 Lassmann H Brunner C Bradl M Linington C. Experimental allergic encephalomyelitis: the balance between encephalitogenic T lymphocytes and demyelinating antibodies determines size and structure of demyelinated lesions. Acta Neuropathol. (1988) 75:566–76. doi: 10.1007/BF00686201, PMID: 3259787 Spadaro M Winklmeier S Beltran E Macrini C Hoftberger R Schuh E . Pathogenicity of human antibodies against myelin oligodendrocyte glycoprotein. Ann Neurol. (2018) 84:315–28. doi: 10.1002/ana.25291, PMID: 30014603 Lucchinetti CF Mandler RN McGavern D Bruck W Gleich G Ransohoff RM . A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica. Brain. (2002) 125:1450–61. doi: 10.1093/brain/awf151 Misu T Fujihara K Kakita A Konno H Nakamura M Watanabe S . Loss of aquaporin 4 in lesions of neuromyelitis optica: distinction from multiple sclerosis. Brain. (2007) 130:1224–34. doi: 10.1093/brain/awm047 Luppe S Robertson NP. MOG-IgG in neuromyelitis optica. J Neurol. (2014) 261:640–2. doi: 10.1007/s00415-014-7277-z